## Mark D Huffman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1154786/publications.pdf

Version: 2024-02-01

212 papers

38,695 citations

47 h-index

47006

189

g-index

225 all docs 225 docs citations

times ranked

225

59194 citing authors

#	Article	IF	CITATIONS
1	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	3.8	13
2	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	2.9	3
3	Eligibility and Prevalence of the American Heart Association Heart Check Certification Program in the US Packaged Food and Beverage Supply: A Cross-Sectional Study. Nutrition and Health, 2022, , 026010602210755.	1.5	O
4	Access to Heart Failure Medicines in Low- and Middle-Income Countries: An Analysis of Essential Medicines Lists, Availability, Price, and Affordability. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008971.	3.9	8
5	Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet Global Health, 2022, 10, e369-e379.	6.3	41
6	Applying systems thinking to identify enablers and challenges to scale-up interventions for hypertension and diabetes in low-income and middle-income countries: protocol for a longitudinal mixed-methods study. BMJ Open, 2022, 12, e053122.	1.9	1
7	Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008552.	2.2	21
8	Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009229.	3.9	5
9	Statin use in low-income and middle-income countries – Authors' reply. The Lancet Global Health, 2022, 10, e955-e956.	<b>6.</b> 3	O
10	Statins for the primary prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD004816.	2.8	933
11	Risk scoring for the primary prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD006887.	2.8	70
12	The Telehealth Ten: A Guide for a Patient-Assisted Virtual Physical Examination. American Journal of Medicine, 2021, 134, 48-51.	1.5	90
13	Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry. International Journal of Cardiology, 2021, 326, 139-143.	1.7	17
14	Twenty-Five-Year Changes in Office and Ambulatory Blood Pressure: Results From the Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Journal of Hypertension, 2021, 34, 494-503.	2.0	5
15	Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. Heart, 2021, 107, 535-541.	2.9	91
16	Association between incarceration and incident cardiovascular disease events: results from the CARDIA cohort study. BMC Public Health, 2021, 21, 214.	2.9	8
17	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	3.1	16
18	The Reply. American Journal of Medicine, 2021, 134, e140.	1.5	0

#	Article	IF	CITATIONS
19	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. Circulation: Heart Failure, 2021, 14, e008090.	3.9	5
20	Systematic reviews of antihypertensive drugs: A review of publication trends, characteristics, and quality. Journal of Clinical Hypertension, 2021, 23, 915-922.	2.0	4
21	Association of Social Network Characteristics With Cardiovascular Health and Coronary Artery Calcium in South Asian Adults in the United States: The MASALA Cohort Study. Journal of the American Heart Association, 2021, 10, e019821.	3.7	8
22	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. American Journal of Clinical Nutrition, 2021, 114, 185-193.	4.7	36
23	Effect of a quality improvement intervention for acute heart failure in South India: An interrupted time series study. International Journal of Cardiology, 2021, 329, 123-129.	1.7	4
24	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	4.4	6
25	Capacity and site readiness for hypertension control program implementation in the Federal Capital Territory of Nigeria: a cross-sectional study. BMC Health Services Research, 2021, 21, 322.	2.2	11
26	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. Journal of Cardiac Failure, 2021, 27, 1214-1221.	1.7	0
27	RESPONSE: Multilateral Cardiovascular Education and Training in Haiti. Journal of the American College of Cardiology, 2021, 77, 2752-2753.	2.8	0
28	Assessment of Studies of Quality Improvement Strategies to Enhance Outcomes in Patients With Cardiovascular Disease. JAMA Network Open, 2021, 4, e2113375.	5.9	9
29	Cardiovascular health and subclinical atherosclerosis in second generation South Asian Americans: The MASALA study. Indian Heart Journal, 2021, 73, 629-632.	0.5	9
30	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	1.7	0
31	Availability, Formulation, Labeling, and Price of Low-sodium Salt Worldwide: Environmental Scan. JMIR Public Health and Surveillance, 2021, 7, e27423.	2.6	28
32	Temporal trends in diagnosis, treatment, and outcome for non-ST-segment elevation acute coronary syndrome in three regions of China, 2008–2015. Chinese Medical Journal, 2021, 134, 1997-1999.	2.3	2
33	Stakeholder perspectives to inform adaptation of a hypertension treatment program in primary healthcare centers in the Federal Capital Territory, Nigeria: a qualitative study. Implementation Science Communications, 2021, 2, 97.	2.2	5
34	Presentation, Management, and In-Hospital Outcomes of Patients with Acute Heart Failure in South India by Sex: A Secondary Analysis of a Prospective, Interrupted Time Series Study. Global Heart, 2021, 16, 63.	2.3	0
35	Barriers and Facilitators to Implementing Reduced-Sodium Salts as a Population-Level Intervention: A Qualitative Study. Nutrients, 2021, 13, 3225.	4.1	7
36	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1133-1146.	13.7	87

3

#	Article	IF	CITATIONS
37	Halving cardiovascular risk with combined blood pressure and cholesterol lowering – Why are we not there yet?. International Journal of Cardiology, 2021, 341, 96-99.	1.7	3
38	Polypills â€" A Central Strategy for Improving Cardiovascular Health. New England Journal of Medicine, 2021, 384, 288-289.	27.0	4
39	Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease. Nutrition Journal, 2021, 20, 3.	3.4	4
40	Healthcare quality and mortality among patients hospitalized for heart failure by hospital level in Beijing, China. ESC Heart Failure, 2021, 8, 1186-1194.	3.1	11
41	Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago. Open Forum Infectious Diseases, 2021, 8, ofaa582.	0.9	46
42	Polypill Eligibility for Patients with Heart Failure With Reduced Ejection Fraction in South India: A Secondary Analysis of a Prospective, Interrupted Time Series Study. Journal of the American Heart Association, 2021, 10, e021676.	3.7	2
43	Disparities in Secondary Prevention between Stroke and Coronary Heart Disease in China: Cross-Sectional Community-Based Study, 2014–2016. Cerebrovascular Diseases, 2021, , 1-10.	1.7	0
44	Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. The Cochrane Library, 2020, 2020, CD011814.	2.8	36
45	Sex Differences in the Presentation, Diagnosis, and Management of Acute Coronary Syndromes: Findings From the Kerala-India ACS Registry. Global Heart, 2020, 10, 273.	2.3	17
46	Investing in Research Training to Improve Global Cardiovascular Health. Global Heart, 2020, 11, 149.	2.3	0
47	Associations between depressive symptoms, cigarette smoking, and cardiovascular health: Longitudinal results from CARDIA. Journal of Affective Disorders, 2020, 260, 583-591.	4.1	22
48	Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. European Journal of Heart Failure, 2020, 22, 646-660.	7.1	38
49	Developing the Core Pillars of Training Global Cardiovascular Health Researchers: Companionship, Light, and Fuel. Global Heart, 2020, 14, 387.	2.3	1
50	Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a doubleâ€blinded, randomizedâ€controlled trial. Journal of Clinical Hypertension, 2020, 22, 1504-1512.	2.0	11
51	Using implementation science to mitigate worsening health inequities in the United States during the COVID-19 pandemic. International Journal for Equity in Health, 2020, 19, 170.	3.5	9
52	Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy. JAMA - Journal of the American Medical Association, 2020, 324, 2259.	7.4	18
53	Monitoring and implementation of salt reduction initiatives in Africa: A systematic review. Journal of Clinical Hypertension, 2020, 22, 1355-1370.	2.0	10
54	Twoâ€drug fixedâ€dose combinations of blood pressureâ€lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. Journal of Clinical Hypertension, 2020, 22, 1769-1779.	2.0	23

#	Article	IF	CITATIONS
55	Patients' perceptions of self-management of high blood pressure in three low- and middle-income countries: findings from the BPMONITOR study. Global Health, Epidemiology and Genomics, 2020, 5, e4.	0.8	4
56	Perspective: Childhood Obesity Requires New Strategies for Prevention. Advances in Nutrition, 2020, 11, 1071-1078.	6.4	38
57	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. Circulation, 2020, 141, 530-539.	1.6	62
58	The American Heart Association 2030 Impact Goal: A Presidential Advisory From the American Heart Association. Circulation, 2020, 141, e120-e138.	1.6	114
59	World Heart Federation Emerging Leaders Program: An Innovative Capacity Building Program to Facilitate the 25 $ ilde{A}$ — 25 Goal. Global Heart, 2020, 10, 229.	2.3	7
60	The Cochrane Heart at <i>Global Heart</i> . Global Heart, 2020, 9, 511.	2.3	0
61	Youth Manifesto on Non-Communicable Diseases. Global Heart, 2020, 6, 201.	2.3	4
62	Trans-Disciplinary Education and Training for NCD Prevention and Control. Global Heart, 2020, 6, 191.	2.3	4
63	Non-Communicable, Chronic Disease Training and Education Needs in India. Global Heart, 2020, 6, 195.	2.3	1
64	Influenza-associated cardiovascular mortality in older adults in Beijing, China: a population-based time-series study. BMJ Open, 2020, 10, e042487.	1.9	16
65	Adverse Trends in Premature Cardiometabolic Mortality in the United States, 1999 to 2018. Journal of the American Heart Association, 2020, 9, e018213.	3.7	19
66	Barriers and facilitators to cessation among tobacco users with concomitant mental illness attending group behavioral tobacco cessation: A qualitative study. Tobacco Prevention and Cessation, 2020, 6, 46.	0.4	5
67	Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality. Global Heart, 2020, 15, 52.	2.3	11
68	Implementation Research to Improve Cardiovascular Disease Management in India's Heterogeneous Primary Healthcare System. The National Medical Journal of India, 2020, 33, 65.	0.3	1
69	Lipoprotein(a) and High Sensitivity C-Reactive Protein among Patients with HIV in Ghana: The Study on Cardiovascular Risk Profile of HIV-Infected Patients on HAART (SCRIPT). Global Heart, 2020, 15, 74.	2.3	4
70	Feasibility and effect of community health worker support and home monitoring for blood pressure control in Nigeria: a randomised pilot trial. Cardiovascular Journal of Africa, 2020, 31, 51-53.	0.4	3
71	Progressing polypills beyond concepts to outcomes. Lancet, The, 2019, 394, 617-619.	13.7	0
72	Association between socioeconomic position and cardiovascular disease risk factors in rural north India: The Solan Surveillance Study. PLoS ONE, 2019, 14, e0217834.	2.5	10

#	Article	IF	Citations
73	The Healthfulness of the US Packaged Food and Beverage Supply: A Cross-Sectional Study. Nutrients, 2019, 11, 1704.	4.1	36
74	Association of cardiovascular health through early adulthood and health-related quality of life in middle age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Preventive Medicine, 2019, 126, 105772.	3.4	12
75	Cardiovascular risk factors among Ghanaian patients with HIV: A crossâ€sectional study. Clinical Cardiology, 2019, 42, 1195-1201.	1.8	14
76	Evaluating the Potential Association Between Lipoprotein(a) and Atherosclerosis (from the Mediators) Tj ETQq0 2019, 123, 919-921.	0 0 rgBT / 1.6	Overlock 10 1 19
77	Hospital-Based Quality Improvement Interventions for Patients With Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005513.	2.2	8
78	Hospital-based quality improvement interventions for patients with heart failure: a systematic review. Heart, 2019, 105, 431-438.	2.9	11
79	Hospital-Level Cardiovascular Management Practices in Kerala, India. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005251.	2.2	3
80	Facilitators and barriers of heart failure care in Kerala, India: A qualitative analysis of health-care providers and administrators. Indian Heart Journal, 2019, 71, 235-241.	0.5	7
81	Microeconomic Costs, Insurance, and Catastrophic Health Spending Among Patients With Acute Myocardial Infarction in India. JAMA Network Open, 2019, 2, e193831.	5.9	11
82	New and Emerging Tobacco Products and the Nicotine Endgame: The Role of Robust Regulation and Comprehensive Tobacco Control and Prevention: A Presidential Advisory From the American Heart Association. Circulation, 2019, 139, e937-e958.	1.6	60
83	Implementation and acceptability of a heart attack quality improvement intervention in India: a mixed methods analysis of the ACS QUIK trial. Implementation Science, 2019, 14, 12.	6.9	4
84	Health-Related Quality of Life at 30 Days Among Indian Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004980.	2.2	8
85	Implementation Strategies for Cardiovascular Polypills. JAMA - Journal of the American Medical Association, 2019, 322, 2279.	7.4	8
86	Efficacy of a group tobacco cessation behavioral intervention among tobacco users with concomitant mental illness in Kenya: protocol for a controlled clinical trial. BMC Public Health, 2019, 19, 1700.	2.9	1
87	Evaluating Longitudinal Associations Between Depressive Symptoms, Smoking, and Biomarkers of Cardiovascular Disease in the CARDIA Study. Psychosomatic Medicine, 2019, 81, 372-379.	2.0	9
88	The Role of Government in Precision Medicine, Precision Public Health and the Intersection With Healthy Living. Progress in Cardiovascular Diseases, 2019, 62, 50-54.	3.1	9
89	Tobacco Cessation Among Acute Coronary Syndrome Patients in Kerala, India: Patient and Provider Perspectives. Qualitative Health Research, 2019, 29, 1145-1160.	2.1	4
90	Footprint and Imprint: An Ecologic Time-Trend Analysis of Cardiovascular Publications in General and Specialty Journals. Global Heart, 2019, 9, 263.	2.3	1

#	Article	IF	CITATIONS
91	Maturing Methods for Cardiovascular Disease and Stroke Surveillance in the United States. JAMA Cardiology, 2018, 3, 390.	6.1	2
92	Modernizing the World Health Organization List of Essential Medicines forÂPreventing and Controlling Cardiovascular Diseases. Journal of the American College of Cardiology, 2018, 71, 564-574.	2.8	40
93	Differences in the sodium content of bread products in the USA and UK: implications for policy. Public Health Nutrition, 2018, 21, 632-636.	2.2	20
94	Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2018, 319, 567.	7.4	62
95	Knowledge, opinions and compliance related to the 100% smoke-free law in hospitality venues in Kampala, Uganda: cross-sectional results from the <i>KOMPLY Project</i> . BMJ Open, 2018, 8, e017601.	1.9	16
96	Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart, 2018, 104, 1238-1243.	2.9	37
97	Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1224-1236.	13.7	101
98	Presentation, Management, and Outcomes of Acute Stroke in Palestine. Journal of the American Heart Association, 2018, 7, e010778.	3.7	6
99	Eat to Treat Heart Failure. Circulation: Heart Failure, 2018, 11, e005367.	3.9	3
100	Cardiovascular Diseases in India Compared With the United States. Journal of the American College of Cardiology, 2018, 72, 79-95.	2.8	76
101	Tools for Evaluating and Improving Causal Inference. JAMA Cardiology, 2018, 3, 907.	6.1	4
102	Different Population and End Point Definitions in Reproduction Analysis Based on Shared Dataâ€"Reply. JAMA Cardiology, 2018, 3, 894.	6.1	4
103	Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2018, 51, 104-112.	2.3	34
104	Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency. JAMA - Journal of the American Medical Association, 2018, 320, 552.	7.4	2
105	In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry. Journal of Cardiac Failure, 2018, 24, 842-848.	1.7	29
106	The 2017 American College of Cardiology/ American Heart Association Clinical Practice Guideline for Blood Pressure: Implications for India. The National Medical Journal of India, 2018, 31, 129.	0.3	2
107	Global Health Research Mentoring Competencies for Individuals and Institutions in Low- and Middle-Income Countries. American Journal of Tropical Medicine and Hygiene, 2018, 100, 15-19.	1.4	31
108	Facilitators, context of and barriers to acute coronary syndrome care at Kenyatta National Hospital, Nairobi, Kenya: a qualitative analysis. Cardiovascular Journal of Africa, 2018, 29, 177-182.	0.4	11

#	Article	IF	Citations
109	Presentation, management and outcomes of acute coronary syndrome: a registry study from Kenyatta National Hospital in Nairobi, Kenya. Cardiovascular Journal of Africa, 2018, 29, 225-230.	0.4	23
110	Evidence-based global cardiovascular disease control priority interventions. Indian Journal of Medical Research, 2018, 148, 247.	1.0	1
111	Association of the von Willebrand Factor–ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 807-813.	1.7	14
112	Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial. American Heart Journal, 2017, 185, 154-160.	2.7	24
113	Global Burden of Raised Blood Pressure. JAMA - Journal of the American Medical Association, 2017, 317, 142.	7.4	14
114	Uses of polypills for cardiovascular disease and evidence to date. Lancet, The, 2017, 389, 1055-1065.	13.7	85
115	Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. The Cochrane Library, 2017, 2017, CD009868.	2.8	49
116	Concomitant Atrial Fibrillation Surgery for People Undergoing Cardiac Surgery. JAMA Cardiology, 2017, 2, 334.	6.1	12
117	Challenges and opportunities in accessing trial data: an example from statin primary prevention trials. Heart Asia, 2017, 9, 99-101.	1.1	0
118	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health, 2017, 5, e665-e672.	6.3	247
119	Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. Vascular Medicine, 2017, 22, 218-224.	1.5	3
120	I Do Not Have Heart Diseaseâ€"Should I Be Taking Aspirin?. JAMA Cardiology, 2017, 2, 824.	6.1	1
121	Improving Blood Pressure Control and Health Systems With Community Health Workers. JAMA - Journal of the American Medical Association, 2017, 318, 1009.	7.4	3
122	Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing. JAMA Cardiology, 2017, 2, 1375.	6.1	14
123	Evaluating and Improving Cardiovascular Health System Management in Low- and Middle-Income Countries. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	5
124	Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	11
125	Implementing Evidence-Based Practices for Acute Stroke Care in Low- and Middle-Income Countries. Current Atherosclerosis Reports, 2017, 19, 61.	4.8	3
126	Evaluating and Improving the Cardiovascular Drug Supply for Better Global Health. JAMA Cardiology, 2017, 2, 225.	6.1	13

#	Article	IF	CITATIONS
127	Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients. Journal of the American College of Cardiology, 2017, 69, 1617-1636.	2.8	55
128	Pre-hospital policies for the care of patients with acute coronary syndromes in India: A policy document analysis. Indian Heart Journal, 2017, 69, S12-S19.	0.5	4
129	Pre-hospital acute coronary syndrome care in Kerala, India: A qualitative analysis. Indian Heart Journal, 2017, 69, 93-100.	0.5	14
130	Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. Circulation, 2017, 135, e793-e813.	1.6	92
131	WHF Emerging Leaders Program. European Heart Journal, 2017, 38, 2800-2803.	2.2	1
132	Could patents interfere with the development of a cardiovascular polypill? Journal of Translational Medicine, 2016, 14, 242.	4.4	7
133	The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke. Circulation, 2016, 133, e674-90.	1.6	155
134	Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2016, 1, 341.	6.1	65
135	Global tobacco prevention and control in relation to a cardiovascular health promotion and disease prevention framework: A narrative review. Preventive Medicine, 2016, 93, 189-197.	3.4	15
136	Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, e38-360.	1.6	5,447
137	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. International Journal of Cardiology, 2016, 204, 133-141.	1.7	108
138	Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. Vascular Medicine, 2016, 21, 120-129.	1.5	21
139	Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation, 2016, 133, 742-755.	1.6	78
140	Executive Summary: Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, 447-454.	1.6	2,093
141	Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study. Vascular Medicine, 2016, 21, 12-20.	1.5	17
142	The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation. Global Heart, 2016, 11, 251.	2.3	26
143	Mediators of Atherosclerosis in South Asians Living in America: Use of Web-Based Methods for Follow-Up and Collection of Patient-Reported Outcome Measures. JMIR Research Protocols, 2016, 5, e95.	1.0	4
144	Implantable defibrillators versus medical therapy for cardiac channelopathies. The Cochrane Library, 2015, , CD011168.	2.8	9

#	Article	IF	CITATIONS
145	Clinical presentation, management, inâ€hospital and 90â€day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. European Journal of Heart Failure, 2015, 17, 794-800.	7.1	105
146	The association between cardiovascular health and health-related quality of life and health status measures among U.S. adults: a cross-sectional study of the National Health and Nutrition Examination Surveys, 2001–2010. Health and Quality of Life Outcomes, 2015, 13, 152.	2.4	34
147	The Polypill: From Promise to Pragmatism. PLoS Medicine, 2015, 12, e1001862.	8.4	24
148	Disparities in Cardiovascular Research Output and Citations From 52 African Countries: A Timeâ€Trend, Bibliometric Analysis (1999–2008). Journal of the American Heart Association, 2015, 4, .	3.7	23
149	Distribution of Shortâ€Term and Lifetime Predicted Risks of Cardiovascular Diseases in Peruvian Adults. Journal of the American Heart Association, 2015, 4, e002112.	3.7	8
150	Executive Summary: Heart Disease and Stroke Statistics—2015 Update. Circulation, 2015, 131, 434-441.	1.6	509
151	Heart Disease and Stroke Statistics—2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
152	Automating data extraction in systematic reviews: a systematic review. Systematic Reviews, 2015, 4, 78.	5.3	150
153	Association of 6â€Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. Journal of the American Heart Association, 2015, 4, .	3.7	27
154	Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF). American Heart Journal, 2015, 170, 627-634.e1.	2.7	29
155	Declining trends in acute myocardial infarction attack and mortality rates, celebrating progress and ensuring future success. Heart, 2015, 101, 1353-1354.	2.9	10
156	Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012. Journal of the American Heart Association, 2015, 4, .	3.7	44
157	Global Cardiovascular Research Training for Implementation Science, Health Systems Research, and Health Policy Research. Journal of the American College of Cardiology, 2015, 65, 1371-1372.	2.8	14
158	Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013. Circulation, 2015, 132, 1667-1678.	1.6	717
159	Building the Case for Clopidogrel as a World Health Organization Essential Medicine. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 447-451.	2.2	13
160	Data Resource Profile: The Cardiovascular Disease Lifetime Risk Pooling Project. International Journal of Epidemiology, 2015, 44, 1557-1564.	1.9	38
161	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	13.7	5,847
162	Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Global Heart, 2015, 10, 99.	2.3	82

#	Article	IF	CITATIONS
163	Requiem for the steth? Not Yet: Are you Listening?. Journal of the Practice of Cardiovascular Sciences, 2015, 1, 225.	0.1	O
164	Fixed dose combinations of cardiovascular drugs. BMJ, The, 2014, 348, g3480-g3480.	6.0	3
165	Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people. BMJ, The, 2014, 348, g1520-g1520.	6.0	3
166	Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
167	Association of 10â€Year and Lifetime Predicted Cardiovascular Disease Risk With Subclinical Atherosclerosis in South Asians: Findings From the Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study. Journal of the American Heart Association, 2014, 3, e001117.	3.7	62
168	Fixed-Dose Combination Therapy (Polypill) for the Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 312, 2030.	7.4	9
169	Formulation of Treatment Recommendations for Statins. JAMA - Journal of the American Medical Association, 2014, 311, 305.	7.4	0
170	Envisioning a Transdisciplinary University. Journal of Law, Medicine and Ethics, 2014, 42, 17-25.	0.9	6
171	Cardiovascular Health in Low- and Middle-Income Countries. Current Problems in Cardiology, 2014, 39, 399-419.	2.4	9
172	Polypills. Journal of the American College of Cardiology, 2014, 63, 1368-1370.	2.8	31
173	Executive Summary: Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, 399-410.	1.6	1,295
174	Fixed-dose combination therapy for the prevention of cardiovascular disease., 2014, , CD009868.		57
175	Vulnerable blood in high risk vascular patients: Study design and methods. Contemporary Clinical Trials, 2014, 38, 121-129.	1.8	11
176	Cardiovascular Research Publications from Latin America between 1999 and 2008. A Bibliometric Study. Arquivos Brasileiros De Cardiologia, 2014, 104, 5-15.	0.8	15
177	D-Dimer in the Months Leading up to Acute Coronary Events: A Case Crossover Study. Blood, 2014, 124, 2864-2864.	1.4	O
178	Lifetime Risk for Heart Failure Among White and Black Americans. Journal of the American College of Cardiology, 2013, 61, 1510-1517.	2.8	183
179	Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2013, 310, 2451.	7.4	117
180	Executive Summary: Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, 143-152.	1.6	1,179

#	Article	IF	CITATIONS
181	Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. European Heart Journal, 2013, 34, 121-129.	2.2	193
182	Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, e6-e245.	1.6	4,387
183	Predictors of carotid intima–media thickness and carotid plaque in young Indian adults: The New Delhi Birth Cohort. International Journal of Cardiology, 2013, 167, 1322-1328.	1.7	32
184	White blood cell count in young adulthood and coronary artery calcification in early middle age: coronary artery risk development in young adults (CARDIA) study. European Journal of Epidemiology, 2013, 28, 735-742.	5.7	22
185	Optimal In-Hospital and Discharge Medical Therapy in Acute Coronary Syndromes in Kerala. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 436-443.	2.2	41
186	Quantifying Options for Reducing Coronary Heart Disease Mortality By 2020. Circulation, 2013, 127, 2477-2484.	1.6	57
187	Trends in Vascular Risk Factor Treatment and Control in US Stroke Survivors. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 270-277.	2.2	25
188	Association between diabetes mellitus and postâ€discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. European Journal of Heart Failure, 2013, 15, 194-202.	7.1	155
189	Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era. Chest, 2013, 144, 1282-1290.	0.8	65
190	Association between Gender, Process of Care Measures, and Outcomes in ACS in India: Results from the Detection and Management of Coronary Heart Disease (DEMAT) Registry. PLoS ONE, 2013, 8, e62061.	2.5	32
191	Global Cardiovascular Research Output, Citations, and Collaborations: A Time-Trend, Bibliometric Analysis (1999–2008). PLoS ONE, 2013, 8, e83440.	2.5	71
192	Heart Failure in North America. Current Cardiology Reviews, 2013, 9, 128-146.	1.5	54
193	Association or Causation of Sugar-Sweetened Beverages and Coronary Heart Disease. Circulation, 2012, 125, 1718-1720.	1.6	10
194	Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. European Journal of Heart Failure, 2012, 14, 302-311.	7.1	159
195	Fixed-dose combination therapy for the prevention of cardiovascular disease., 2012,,.		1
196	Novel Treatments for Cardiovascular Disease Prevention. Cardiovascular Therapeutics, 2012, 30, 257-263.	2.5	12
197	Cardiovascular Health Behavior and Health Factor Changes (1988–2008) and Projections to 2020. Circulation, 2012, 125, 2595-2602.	1.6	254
198	Impact of comprehensive cardiovascular risk reduction programme on risk factor clustering associated with elevated blood pressure in an Indian industrial population. Indian Journal of Medical Research, 2012, 135, 485-93.	1.0	12

#	Article	IF	CITATIONS
199	Incidence of Cardiovascular Risk Factors in an Indian Urban Cohort. Journal of the American College of Cardiology, 2011, 57, 1765-1774.	2.8	68
200	Does Low Pre-Test Probability of Coronary Artery Disease Reflect Overuse of Stress Testing?. JACC: Cardiovascular Imaging, 2011, 4, 1143-1144.	5.3	6
201	Regarding the Prevention of Global Chronic Disease: Academic Public Health's New Frontier. American Journal of Public Health, 2011, 101, 2196-2197.	2.7	0
202	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. Current Cardiovascular Risk Reports, 2011, 5, 280-286.	2.0	0
203	Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open, 2011, 1, e000068-e000068.	1.9	27
204	A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries. PLoS ONE, 2011, 6, e20821.	2.5	149
205	A new approach to resident morning report: introducing "VAVUM― Internal and Emergency Medicine, 2010, 5, 81-82.	2.0	8
206	Global Chronic Disease Research Training for Fellows. Circulation, 2010, 121, 1365-1370.	1.6	11
207	Cardiovascular Health in Indigenous Communities: Successful Programs. Heart Lung and Circulation, 2010, 19, 351-360.	0.4	27
208	Heart failure: epidemiology and prevention in India. The National Medical Journal of India, 2010, 23, 283-8.	0.3	68
209	Clinical Practice Guidelines and Scientific Evidence. JAMA - Journal of the American Medical Association, 2009, 302, 142.	7.4	2
210	Factors associated with enrollment of African Americans into a clinical trial: Results from the African American study of kidney disease and hypertension. Contemporary Clinical Trials, 2008, 29, 837-842.	1.8	62
211	Pulmonary arterial hypertension: New management options. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 451-458.	0.9	0
212	Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country. , 0, 2, .		0